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OBJECTIVE. To assess the added value of neurite orientation dispersion and density imaging 
(NODDI) compared to conventional DTI and anatomical MRI to detect changes in 
presymptomatic carriers of chromosome 9 open reading frame 72 (C9orf72) mutation. 
METHODS. The PREV-DEMALS study is a prospective, multicenter, observational study of 
first-degree relatives of individuals carrying the C9orf72 mutation. Sixty-seven participants (38 
presymptomatic C9orf72 mutation carriers [C9+], 29 non carriers [C9-]) were included in the 
present cross-sectional study. Each participant underwent one single-shell, multi-shell diffusion 
MRI and 3DT1 MRI. Volumetric measures, DTI and NODDI metrics were calculated within 
regions of interest. Differences in white matter integrity, gray matter volume and free water 
fraction between C9+ and C9− individuals were assessed using linear mixed-effects models.  
RESULTS. Compared with C9-, C9+ demonstrated white matter abnormalities in 10 tracts 
with neurite density index, and only 5 tracts with DTI metrics. Effect size was significantly 
higher for the neurite density index than for DTI metrics in two tracts. No tract had a 
significantly higher effect size for DTI than for NODDI. For gray matter cortical analysis, free 
water fraction was increased in 13 regions in C9+, whereas 11 regions displayed volumetric 
atrophy.  
CONCLUSIONS. NODDI provides higher sensitivity and greater tissue-specificity compared 
to conventional DTI for identifying white matter abnormalities in the presymptomatic C9orf72 
carriers. Our results encourage the use of neurite density as biomarker of the preclinical phase. 








Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are two 
degenerative diseases that share common genetic causes, the most frequent being a GGGGCC 
repeat expansion in the chromosome 9 open reading frame 72 (C9orf72) gene.1,2 Early stages 
of C9orf72 carriers have received much interest, because presymptomatic carriers represent the 
optimal target population for the development of new disease-modifying treatments against 
FTLD and ALS. Anatomical magnetic resonance imaging (MRI) derived metrics, such as 
volumetry, have revealed brain atrophy in presymptomatic individuals who carry the C9orf72 
mutation (C9+).3,4,5,6,7,8,9 Three studies5,6,8 also detected disruptions of white matter integrity 
using diffusion tensor imaging (DTI) technique, whereas another study failed to identify such 
abnormalities.4 The DTI results are promising but with limitations. First, DTI metrics, such as 
fractional anisotropy (FA), are non-specific biomarker of microstructural architecture.10,11 For 
instance, FA changes could be underpinned by combinations of neurite density reduction and 
orientation dispersion changes.12 Besides, DTI is limited when an image voxel suffers from 
partial volume effect. Neurite orientation dispersion and density imaging (NODDI) was 
proposed to characterize alterations of microstructural integrity with higher tissue-specificity.12 
NODDI derives a neurite density index (NDI) and orientation dispersion index (ODI) to 
quantify the density and angular variation of neurites, respectively. In addition, NODDI 
includes a free water fraction (FWF) parameter designed to capture the contamination of tissues 
by free water at the microstructural level.  
In the present work, we assess the added value of NODDI compared to conventional 
DTI and anatomical MRI to detect changes at the presymptomatic phase of C9orf72 disease. 
We hypothesize that NDI and ODI offer higher sensitivity than FA, mean diffusivity (MD), 






Additionally, FWF is compared with volumetry and may provide complementary information 
for identifying gray matter changes.  
 
Material and Methods 
Participants 
Eighty-six first-degree relatives of C9orf72 mutation carriers from 48 families were enrolled in 
an ongoing national multicentric study (PREV-DEMALS) between October 2015 and October 
2017. This study was approved by the Comité de Prévention des Personnes Ile de France VI of 
the Hôpital Pitié-Salpêtrière, and written informed consent was obtained from all participants. 
At inclusion, asymptomatic status of participants was ascertained based on relative’s interview, 
neurological examination, and the normality of behavioral scales and neuropsychological 
scores, taking into account age and educational level. In the present study, sixty-seven 
neurologically healthy participants, who underwent a single-shell diffusion weighted image 
(DWI) sequence, a multi-shell DWI sequence and a 3DT1 sequence, were included in the 
analyses. C9orf72 genetic status was determined by repeat-primed polymerase chain reaction 
on lymphocytes DNA. Thirty-eight C9+ participants carried a pathogenic expansion (>23 
GGGGCC repeats); twenty-nine control participants did not carry this expansion (C9−). The 
study population characteristics are shown in Table 1. Demographic characteristics and clinical 
tests were compared between groups using the 𝜒"  test for dichotomous and categorical 
variables or Mann-Whitney test for numerical variables. There was no statistical difference 
between C9+ and C9- regarding age at inclusion (P = 0.18), gender (P = 0.65) and clinical 
scores (Mini-Mental State Examination, P = 0.83; Mattis dementia rating scale, P = 0.37; 








Table 1. Study Group Characteristics.  
Expected ages at onset of C9orf72 carriers were estimated by averaging the ages at onset of 
affected relatives, as in a previous study3.  
Abbreviations: MMSE, Mini-Mental State Examination; MDRS, Mattis dementia rating scale; 
FAB, Frontal assessment battery; NA, not applicable. Results are given as mean (standard 
deviation) or number (percentage). 
 
 Mean (SD)  
Characteristics C9− (n = 29) C9+ (n = 38) P value 
Demographic characteristics    
 Age, y 44.8 (13.5) 40.7 (11.5) 0.18 
 Female, No. (%) 17 (59) 19 (50) 0.65 
 Right laterality, No. (%)  24 (83)  33 (87)  0.91 
 Expected time to onset, years NA 18.6 (11.4) NA 
Family phenotype, No. (%)    
 FTLD 12 (42) 18 (47)  
 
0.91 
 ALS 2 (7) 3 (8) 
 FTLD and ALS 14 (48) 17 (45) 
 Unavailable 1 (3) 0  
Neuropsychological scores    
 MMSE score (maximum, 30) 28.7 (1.2) 28.5 (1.5) 0.83 
 FAB (maximum, 18) 16.9 (1.3) 17.1 (1.2) 0.40 
 MDRS score (maximum, 144) 141.9 (2.2) 141.3 (2.7) 0.37 
 
MRI acquisition  
All MRI acquisitions were performed on a 3-T MRI system (Siemens Prisma Syngo 3T) in a 
single center (Paris) belonging to the harmonized national network of the Centre d’Acquisition 
et de Traitement d’Images (http://cati-neuroimaging.com/).13 The Centre d’Acquisition et de 
Traitement d’Images performed onsite visits for the setup of imaging protocols and regular 
follow-up. Each participant underwent a 3DT1 sequence with the following parameters: voxel 
size 1.1x1.1x1.1 mm3; TE/TR = 2.93/2200 ms; Bandwidth = 240 Hz. One single-shell DWI 
sequence with two repeats was acquired for DTI with the following parameters: voxel size 
2.5x2.5x2.5 mm3; TE/TR = 90/7300 ms; Bandwidth = 1580 Hz; 64 diffusion-weighted 
directions, b-value = 1000 s/mm2, 9 T2-weighted images (b-value = 0 s/mm2, referred to as b0 






field. One three-shell DWI sequence with two repeats was acquired with reversed phase 
encoding directions for NODDI model: voxel size 2x2x2 mm3; TE/TR = 70/3000 ms; 
Bandwidth = 2090 Hz; 60, 32 and 9 diffusion-weighted directions at b-value = 2200, 700 and 
300 s/mm2 respectively; 13 b0 images. Of note, the DTI analysis was based on the single-shell 
data (b=1000 s/mm2). Indeed, DTI model is known to be a poor representation of the DWI 
signals at the high b-value (> 2000). On the other hand, the low b-values (300 and 700) are 
acquired at prolonged TE designed to accommodate the high b-value. So these low b-values 
data are not representative of standard DTI data. Systematic quality checks of MRI results were 
performed by the Centre d’Acquisition et de Traitement d’Images as in previous work.6 All 
images were of satisfactory quality except for one T1 acquisition and one single-shell DWI 
acquisition from different individuals. These two images were excluded respectively from gray 
matter and white matter analyses.  
 
Anatomical MRI processing 
T1-weighted images were processed with the FreeSurfer image analysis suite (Version 5.3; 
https://surfer.nmr.mgh.harvard.edu/), including skull stripping, intensity normalization, cortical 
and subcortical segmentation, cortical surface reconstruction and parcellation of the cortex 
using the Desikan-Killiany atlas14. We studied gray matter volumes of 68 cortical regions of 
interest (ROIs) and 18 subcortical ROIs. The list of regions is provided in Supplementary 




The single-shell DWI data were processed with the same approach as in previous work.6 To 






average b0 image, and an affine registration was used to correct for eddy current-induced 
distortions. The field map image was used to estimate the susceptibility-induced off-resonance 
field.15 A single multiplicative bias field from the averaged b0 image was estimated and applied 
to the single-shell DWI data.16 FA, MD, RD and AD were estimated using an iteratively 
reweighted linear least squares estimator.17 Each individual FA map was aligned onto the JHU 
white-matter tractography atlas template18 with a rigid plus deformable registration.19 MD, AD 
and RD maps were subsequently registered into the JHU atlas using the transformation field 
from the previous step. The regional mean values of FA, MD, AD and RD maps were extracted. 
The list of regions is provided in Supplementary material (supplementary-appendix e-2).  
 
NODDI processing 
From the pairs of images with reversed phase encoding directions, the susceptibility-induced 
off-resonance field was estimated using topup tool.20 Besides, eddy current-induced distortions 
and subject movements were corrected by simultaneously modelling the effects of diffusion 
eddy currents and movements on the image using eddy tool.21 The b-vector was subsequently 
corrected. The NODDI model was then fitted to the artifact-corrected data, generating NDI, 
ODI and FWF maps using NODDI Matlab toolbox 
(https://www.nitrc.org/projects/noddi_toolbox). For white matter analysis, DTI model was 
applied to the middle-shell data (b-value = 700 s/mm2) to generate the FA map, in order to 
estimate the transformation field from the native diffusion space to the JHU space. Then NDI 
and ODI maps were registered into the JHU space using the transformation field obtained from 
the previous step. Finally, the regional mean values of NDI and ODI were calculated.  
For gray matter analysis, the normalized skull-stripped T1 image in FreeSurfer 
conformed space was rigidly registered onto the first b0 image of the artifact-corrected multi-






FreeSurfer conformed space with a linear interpolation. For subcortical ROI analysis, a 2-voxel 
morphological erosion operator was performed on each segmented subcortical ROI.22 For 
cortical ROI analysis, FWF signal was projected onto cortical middle surface. The projected 
FWF value was calculated with a weighted average of signals from the seven intermediate 
surfaces, which were expanded at different fraction of cortical thickness (35%, 40%, 45%, 50%, 
55%, 60% and 65%) from the white surface. Subsequently, the averaged middle surface was 
registered onto the FsAverage template in FreeSurfer conformed space using a surface-based 
registration method.23 The aim of the erosion and middle surface projection approach was to 
avoid the partial volume effect (i.e., elimination of free water contamination at the edges of 
ventricle and the borders of the brain parenchyma). Finally, the regional mean values of FWF 
were extracted for further cortical and subcortical analyses. 
 
Statistical analysis 
All statistical analyses were performed with R Version 3.4.0 (The R Foundation). Structural 
and microstructural differences between C9+ and C9− participants were assessed using linear 
mixed-effects models. We used real age, gender and group (i.e., mutation status) as fixed effects 
and family membership as random effect measuring the difference between the average 
response in the family and in the whole population (supplementary-appendix e-3). Likelihood 
ratio test was used to test each effect and P values were corrected by the Benjamini-Hochberg 
method with a significance level of P < 0.05. Besides, the effect size of each ROI between C9+ 
and C9- was also reported using Cohen’s f2. Effect sizes obtained for different models or 
metrics (e.g., NODDI vs DTI) were compared using permutation tests with 10000 iterations for 
significant ROIs.  
 
Results 






Figure 1 displays altered white matter tracks after correction for multiple comparisons. 
Compared with C9-, C9+ showed extensive alterations in white matter integrity (i.e., reduced 
NDI, elevated MD, AD and RD), involving several fronto-temporal related tracts (i.e., bilateral 
inferior fronto-occipital fasciculus, bilateral inferior longitudinal fasciculus, right uncinate 
fasciculus, right anterior thalamic radiation, forceps minor) and both cortico-spinal tracts. 10 
tracts were significantly altered in C9+ with NDI, and only 5 tracts with DTI metrics (MD, AD 
or RD). Results before correction for multiple comparisons are shown in supplementary 
material (supplementary-figure e-1). Effect size results confirmed that NDI was more sensitive 
than DTI metrics: among the 11 tracts in which significant differences were detected in either 
NDI or DTI metrics (MD, AD or RD), 7 tracts had higher effect size with NDI than with DTI 
metrics (Figure 2). The effect size was significantly higher with NDI than with DTI for two of 
these tracts: left inferior fronto-occipital fasciculus (P = 0.009) and right uncinate fasciculus (P 
= 0.008). None of the tracts had a significantly higher effect size with DTI than with NDI. 







Figure 1. White Matter Alterations in C9orf72 Mutation Carriers. Color-coded 
representation of P values corresponding to the associations of C9orf72 mutation with white 
matter integrity, both before (left) and after (right) correction for multiple comparisons. 
Abbreviations: FA, fractional anisotropy; MD, mean diffusivity; AD, axial diffusivity; RD, 








Figure 2. Effect Size of White Matter Alterations in C9orf72 Mutation Carriers. Effect 
size (Cohen’s f2) corresponding to the associations of C9orf72 mutation with white matter 
integrity. Only ROIs in which significance was detected in either NDI or DTI metrics are 
displayed. Abbreviations: ART, anterior thalamus radiation tract; CST, cortico-spinal tract; 
Fmajor, forceps major tract; Fminor, forceps minor tract; IFOF, inferior fronto-occipital 
fasciculus; IFOF, inferior fronto-occipital fasciculus; ILF, inferior longitudinal fasciculus; 






fasciculus (temporal part); R., right; L., left; NDI, neurite density index; DTI, diffusion tensor 
imaging. 
 
Cortical gray matter analysis 
Figure 3 displays altered cortical regions after correction for multiple comparisons. Compared 
with C9-, C9+ showed reduced cortical gray matter volume and elevated FWF. 13 ROIs were 
significantly altered with FWF (4 frontal, 1 temporal, 4 parietal, 3 occipital and the left insula), 
and 11 ROIs with volumetry (2 frontal, 5 temporal and 4 parietal ROIs). Results before 
correction for multiple comparisons are shown in supplementary material (supplementary-
figure e-2). Figure 4 displays effect sizes for the 21 regions that were significantly altered 
according to either FWF or volumetry. Among the 21 regions, the left insula (P = 0.002), the 
lateral occipital cortex (P = 0.001) and the left pericalcarine cortex (P = 0.008) had a 
significantly higher effect size with FWF than with volumetry. Only the left temporal pole 
cortex showed significantly higher effect size with volumetry than with FWF (P = 0.02). Effect 
size results are shown in supplementary material (supplementary-table e-2). 
 
Figure 3. Cortical Alterations in C9orf72 Mutation Carriers. Color-coded representation 
of P values corresponding to the associations of C9orf72 mutation with the cortical ROI 
measures, both before (left) and after (right) correction for multiple comparisons. 







Figure 4. Effect Size of Cortical Alterations in C9orf72 Mutation Carriers. Effect size 
(Cohen’s f2) corresponding to the associations of C9orf72 mutation with the cortical ROI 
measures. Only ROIs in which significance was detected in either volumetry or FWF are 
displayed. Abbreviations: CMF, caudal middle frontal cortex; CUN, cuneus cortex; FUS, 
fusiform; IP, inferior parietal cortex; IT, inferior temporal cortex; INS, insula; LO, lateral 
occipital cortex; LIN, lingual; PPC, pars opercularis cortex; PCC, pericalcarine; POC, 






parietal cortex; SM, supramarginal cortex; TP, temporal pole cortex; MOF, medial 
orbitofrontal cortex; R., right; L., left; FWF, free water fraction. 
 
Subcortical gray matter analysis 
Compared with C9-, C9+ showed subcortical volume reduction of the right thalamus after 
correction for multiple comparisons. FWF failed to detect any significant alterations (Figure 5). 
Results before correction for multiple comparisons are presented in supplementary material 
(supplementary-figure e-3). The right thalamus did not show statistically higher effect size with 
volumetry than with FWF (P = 0.062). Effect size results are shown in supplementary material 
(supplementary-table e-3). 
 
Figure 5. Subcortical Alterations in C9orf72 Mutation Carriers. Color-coded 
representation of P values corresponding to the associations of C9orf72 mutation with the 
subcortical ROI measures, both before (left) and after (right) correction for multiple 








The current study, for the first time, compared NODDI to conventional DTI and anatomical 
MRI in a large cohort of presymptomatic C9orf72 carriers. There are three key findings. First, 
we demonstrate that NODDI provides higher sensitivity than DTI for detecting white matter 
microstructural changes. Second, the greater tissue-specificity of NODDI suggests that the 
reduction of neurite density is a more likely cause of signal changes than the alterations of 
neurite orientation dispersion during the presymptomatic stage. Third, the pattern of FWF 
alterations slightly differs from that of gray matter volumetric atrophy, suggesting that both 
FWF and volumetry provide complimentary information on the integrity of cortical and 
subcortical structures.  
When comparing the multi-shell DWI sequence with the standard single-shell DWI 
sequence, we hypothesized that NODDI could be more sensitive than conventional DTI for 
detecting white matter abnormalities during the presymptomatic stage. Previous works have 
shown that NODDI could be more sensitive than DTI for detecting white matter changes related 
to aging24 or young onset Alzheimer’s disease.25 Here, for the first time, we show that NODDI 
outperformed DTI for identifying white matter abnormalities during the presymptomatic stage 
of a neurodegenerative disease. The spatial pattern of white matter changes is consistent with 
previous findings with conventional DTI5,6,8. Specifically, reduced NDI was mainly found in 
the cortico-spinal tract and frontal-temporal related tracts during the presymptomatic stage for 
C9orf72 carriers, which were preferentially involved in symptomatic mutation carriers who 
develop FTLD, ALS or both. On the other hand, to the best of our knowledge, there has been 
no prior study using NODDI in C9orf72 disease, neither at the presymptomatic nor at the 
symptomatic stage. 
The interpretation of specificity for DTI metrics has been discussed,26,27 suggesting that 






specific information than FA. However, these interpretations were also argued in the 
literature.28 Compared with DTI, the more biophysically motivated NODDI model allows more 
direct analysis of independent microstructural effects: the loss of neurite density and the 
alteration of neurite orientation dispersion. This potential for greater tissue-specificity has 
motivated application of NODDI in a few neurodegenerative disease studies29,30,31,25,32. In 
young onset Alzheimer’s disease, one study showed widespread NDI reduction and regional 
ODI reduction in the corpus callosum and internal capsule of patients.25 In Parkinson disease, 
another study observed reduced NDI in the substantia nigra and putamen of patients31. In the 
present study, we detected widespread NDI decrease in the white matter, but no alteration of 
ODI (Figure 1). This suggests that the reduction of neurite density, not the alterations of neurite 
orientation dispersion, is the predominant pathological process in white matter during the 
presymptomatic stage of C9orf72 carriers. Interestingly, similar reduction of neurite density 
within cortico-spinal tract have been found in ALS patients.33 Our observation suggests that the 
neurite loss is the main pathological process, but this needs further histological confirmation. 
We note however that Grussu et al have demonstrated, in the tissue specimen of multiple 
sclerosis, that ODI correlated well with histological measures of neurite orientation dispersion, 
and NDI with histological measures of neurite density.32  
Mapping the free water in tissues is important in order to estimate the variations in 
extracellular volume (related to free water fraction) due to pathological processes.34 FWF has 
been applied in several neurodegenerative diseases. Using a bi-tensor model, FWF has been 
demonstrated as an imaging biomarker of progression of Parkinson’s disease in the posterior 
substantia nigra.35,36 Interestingly, a chronic treatment effect of rasagiline, an irreversible 
inhibitor of monoamine oxidase-B as a medical monotherapy, has been verified with FWF in 
basal ganglia in Parkinson’s disease.37 These findings support the use of FWF as a promising 






present study, FWF detected free water alterations mainly in frontal and temporal lobes. This 
finding is consistent with previous studies using volumetric measure.3,4,5,6,7,8,9 The unique 
differences detected with FWF in left insula and left lateral occipital lobe were also reported in 
literatures using volumetric measure.3,4,5,7 These suggest that macroscopic brain atrophy may 
accompany free water alterations inside the cortex. Surprisingly, FWF failed to show changes 
in subcortical structures, such as the thalamic atrophy where a significant effect of C9orf72 
mutation was evidenced by volumetry. These findings suggest that distinct degenerative 
processes could occur in cortical and subcortical structures at the same time during the 
presymptomatic stage.  
Reliability of an imaging technique is an important issue for its use in clinical trials. We 
do not have test-retest scans in our participants. However, the reliability of NODDI has been 
assessed in previous studies.38,39 NODDI metrics were shown to have excellent reproducibility 
with coefficients of variation below 5% in all measured regions of interest and even below 3% 
in the vast majority of regions.39 Furthermore, the reproducibility of NODDI metrics was shown 
to be comparable to that of conventional DTI.38 This, together with its higher sensitivity to 
detect white matter alterations, supports the use of NODDI in clinical trials.  
 
Limitations 
Our study has the following limitations. First, the cross-model comparison between NODDI 
and DTI used two different DWI acquisitions, which were performed within one week 
sequentially for each participant. However, the single-shell and multi-shell DWI sequences 
were optimized for DTI and NODDI model, respectively. Thus, this systematic comparison 
helps clarify the added value of a longer but clinically feasible multi-shell diffusion sequence. 
Second, caution should be exercised in diffusion MRI-based cortical analysis. NODDI, by 






influence of atrophy on the NODDI metrics. Moreover, a recent paper40 has explicitly looked 
at the influence of cortical thickness on NODDI metrics, showing that the majority of changes 
in NODDI metrics persisted following adjustment for cortical thickness. Nevertheless, the 
cortex is a thin structure compared to the resolution of diffusion MRI and partial volume effect 
may impact on the computation of regional FWF measures. Although we implemented specific 
image processing procedures to mitigate partial volume effects, it is still possible that some 
partial volume effect remains, impacting on FWF estimates. 
 
Conclusion 
In conclusion, this study evaluated the added value of NODDI in detection of brain 
microstructural changes in presymptomatic C9orf72 carriers. NODDI offers higher sensitivity 
compared to conventional DTI for detecting white matter integrity abnormalities. Moreover, it 
offers the potential to reveal a more specific substrate of white matter damage, suggesting here 
that it consists mainly of reduced neurite density. Our results encourage the use of a multi-shell 
DWI sequence in clinical studies and highlight the potential use of NODDI to track the 
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Appendix e-1. Regions for gray matter analyses. 
 
We studied the following 68 cortical regions obtained from the Desikan-Killiany atlas: 
Frontal lobe: left frontal pole, left medial orbitofrontal, left lateral orbitofrontal, left pars 
orbitalis, left pars triangularis, left pars opercularis, left rostral middle frontal, left caudal, 
middle frontal, left superior frontal, left precentral, right frontal pole, right medial orbitofrontal, 
right lateral orbitofrontal, right pars orbitalis, right pars triangularis, right pars opercularis, right 
rostral middle frontal, right caudal middle frontal, right superior frontal, right precentral. 
Temporal lobe: left temporal pole, left banks sts, left transverse temporal, left superior 
temporal, left middle temporal, left inferior temporal, left fusiform, left entorhinal, left 
parahippocampal, right temporal pole, right banks sts , right transverse temporal, right superior 
temporal, right middle temporal, right inferior temporal, right fusiform, right entorhinal, right 
parahippocampal. 
Parietal lobe: left postcentral, left superior parietal, left inferior parietal, left precuneus, left 
supramarginal, left paracentral, right postcentral, right superior parietal, right inferior parietal, 
right precuneus, right supramarginal, right paracentral. 
Occipital lobe: left lingual, left lateral occipital, left cuneus, left pericalcarine, right lingual, 
right lateral occipital, right cuneus, right pericalcarine. 
Cingulate gyrus: left rostral anterior cingulate, left caudal anterior cingulate, left isthmus 
cingulate, left posterior cingulate, right rostral anterior cingulate, right caudal anterior 
cingulate, right isthmus cingulate, right posterior cingulate. 
Insula: left insula, right insula. 
 
The following 18 subcortical regions were included for gray matter volume analyses: 
left cerebellum cortex, right cerebellum cortex, left ventral diencephalon, right ventral 
diencephalon, left putamen, right putamen, left pallidum, right pallidum, left caudate, right 
caudate, left accumbens area, right accumbens area, left amygdala, right amygdala, left 
thalamus proper, right thalamus proper, left hippocampus, right hippocampus. 
 
The following 12 subcortical regions were included for gray matter FWF analyses. The other 6 
ROIs were excluded because, after the 2-voxel erosion procedure, they were too small to 
produce reliable regional estimates. 
left putamen, right putamen, left pallidum, right pallidum, left caudate, right caudate, left 




Appendix e-2: Regions for white matter analyses. 
 
We studied the following 20 tracts based on JHU atlas for white matter analyses:  
left anterior thalamic radiation, right anterior thalamic radiation, left corticospinal tract, right 
corticospinal tract, left cingulum cingulate gyrus, right cingulum cingulate gyrus, left cingulum 
hippocampus, right cingulum hippocampus, forceps major, forceps major, left inferior fronto-
occipital fasciculus, right inferior fronto-occipital fasciculus, left inferior longitudinal 
fasciculus, right inferior longitudinal fasciculus, left superior longitudinal fasciculus, right 
superior longitudinal fasciculus, right uncinate fasciculus, left uncinate fasciculus, left superior 








Appendix e-3. Mixed effects model.  
 
Group differences between carriers and non-carriers of the C9orf72 mutation were assessed 
using linear mixed-effects models. We used age, gender and group (i.e., mutation status) as 
fixed effects, and family membership as random effect, with the following model: 
 
𝑌$%(') = 𝜇 + 𝛽	 ×	𝐺𝑒𝑛𝑑𝑒𝑟$ + 𝜆	 ×	𝐴𝑔𝑒$	 + 𝜂	 ×	𝐺𝑟𝑜𝑢𝑝$ + U% 	+ 𝐸$%(')	 
 
where Y>?(@) is the response of the jBC	region of interest (ROI) for the iBC subject and the	kBC 
family; Gender>	, Age>	  and Group>  are the fixed effects; µ , β , λ  and η  are their estimated 
parameters; U? is the random effect measuring the difference between the average response in 





Figure e-1. Color-coded representation of P values corresponding to the 
associations of C9orf72 mutation with white matter integrity before 
correction for multiple comparisons. 
Abbreviations: FA, fractional anisotropy; MD, mean diffusivity; AD, axial diffusivity; RD, 








Table e-1. Effect sizes for DTI metrics and for NDI in white matter tracts. 
The effect sizes for both NDI and DTI are shown below. For DTI, only the largest effect size 
among the different DTI metrics is shown. For regions for which a significant difference 
between C9+ and C9- was detected for any of the metrics, we compared the effect size of 
NODDI to that of DTI using a permutation test procedures with 10000 iterations. The table 
presents the P values corresponding to these permutation tests (with a significance level of P < 
0.05).  
Abbreviations: ART, anterior thalamus radiation tract; CST, cortico-spinal tract; CCG, 
Cingulum (cingulate gyrus) tract; CH, Cingulum (hippocampus) tract; Fmajor, forceps major 
tract; Fminor, forceps minor tract; IFOF, inferior fronto-occipital fasciculus; ILF, inferior 
longitudinal fasciculus; SLF, superior longitudinal fasciculus; UF, uncinate fasciculus; SLFT, 
superior longitudinal fasciculus (temporal part); R., right; L., left; NDI, neurite density index; 
DTI, diffusion tensor imaging; NA, not applicable. 
 
 
ROI Effect size 
(NDI/DTI) 
P value ROI Effect size 
(NDI/DTI) 
P value 
L.ART 0.06/0.04 NA L.IFOF 0.2/0.21 0.773 
R.ATR 0.12/0.09 0.365 R.IFOF 0.27/0.11 0.009* 
L.CST 0.05/0.07 NA L.ILF 0.09/0.23 0.051 
R.CST 0.09/0.03 0.154 R.ILF 0.16/0.17 0.719 
L.CCG 0.03/0.04 NA L.SLF 0.08/0.06 NA 
R.CCG 0.02/0.02 NA R.SLF 0.13/0.07 0.139 
L.CH 0.01/0.05 NA L.UF 0.03/0.02 NA 
R.CH 0.07/0.01 NA R.UF 0.17/0.01 0.008* 
Fmajor 0.09/0.05 0.207 L.SLFT 0.06/0.05 NA 





Figure e-2. Color-coded representation of P values corresponding to the 
associations of C9orf72 mutation with the cortical ROI measures before 
correction for multiple comparisons. 











Table e-2: Effect sizes for FWF metrics and gray matter volume in cortical 
regions. 
The effect sizes for both FWF and gray matter volume in cortical regions are shown below. For 
regions for which a significant difference between C9+ and C9- was detected for any of the 
metrics, we compared the effect size of FWF to that of volumetry using a permutation test 
procedures with 10000 iterations. The table presents the P values corresponding to these 
permutation tests (with a significance level of P < 0.05).  
Abbreviations: CMF, caudal middle frontal cortex; CUN, cuneus cortex; FUS, fusiform; IP, 
inferior parietal cortex; IT, inferior temporal cortex; INS, insula; LO, lateral occipital cortex; 
LIN, lingual; PPC, pars opercularis cortex; PCC, pericalcarine; POC, postcentral cortex; PREC, 
precuneus; RMF, rostral middle frontal cortex; SP, superior parietal cortex; SM, supramarginal 
cortex; TP, temporal pole cortex; MOF, medial orbitofrontal cortex; BK, bankssts cortex; CAC, 
caudal anterior cingulate cortex; ENT, entorhinal cortex; FP, frontal pole cortex; IC, isthmus 
cingulate cortex; LOF, lateral orbitofrontal cortex; MT, middle temporal cortex; PAC, 
paracentral cortex; PHC, para hippocampal cortex; PB, pars orbitalis cortex; PTR, pars 
triangularis cortex; PCG, posterior cingulate cortex; PRC, precentral cortex; RAC, rostral 
anterior cingulate cortex; SF, superior frontal cortex; ST, superior temporal cortex; TT, 
transverse temporal cortex; R., right; L., left; FWF, free water fraction; NA, not applicable. 
  
ROI Effect size 
(FWF/Volumetry) 
P value ROI Effect size 
(FWF/Volumetry) 
P value 
L.CMF 0.06/0.12 0.734 L.PREC 0.12/0.23 0.466 
L.CUN 0.06/0.03 0.653 L.RMF 0.1/0 0.052 
L.FUS 0.09/0.12 0.305 L.SP 0.1/0.09 0.712 
L.IP 0.11/0.01 0.072 L.SM 0.11/0.18 0.639 
L.IT 0.17/0.14 0.259 L.TP 0/0.12 0.025* 
L.INS 0.19/0 0.002* R.FUS 0.06/0.17 0.096 
L.LO 0.32/0.09 0.001* R.IT 0.07/0.15 0.406 
L.LIN 0.11/0.06 0.092 R.MOF 0.12/0.02 0.051 
L.PPC 0.12/0.06 0.201 R.PREC 0.07/0.14 0.483 
L.PCC 0.12/0.01 0.008* R.SP 0.03/0.14 0.140 
L.POC 0.09/0.08 0.558 L.PB 0.08/0 NA 
R.CMF 0.04/0.06 NA L.PTR 0.08/0.01 NA 
L.BK 0.08/0.01 NA L.PCG 0.06/0 NA 
L.CAC 0.04/0.01 NA L.PRC 0.07/0.09 NA 
L.ENT 0.02/0.01 NA L.RAC 0/0.01 NA 
L.FP 0.02/0.1 NA L.SF 0.06/0.11 NA 
L.IC 0.01/0.02 NA L.ST 0.01/0.04 NA 
L.LOF 0.11/0.06 NA L.TT 0.01/0.04 NA 
L.MOF 0.01/0.01 NA R.BK 0.05/0.01 NA 
L.MT 0.08/0.01 NA R.CAC 0.04/0.03 NA 
L.PAC 0.02/0.02 NA R.CUN 0/0.04 NA 
L.PHC 0.07/0 NA R.ENT 0.06/0 NA 
R.FP 0.04/0 NA R.IP 0.01/0.01 NA 
R.INS 0.05/0.02 NA R.IC 0.04/0 NA 
R.LOF 0.08/0.01 NA R.LO 0.06/0.04 NA 
R.LIN 0.04/0.02 NA R.MT 0.06/0.07 NA 
R.PAC 0.05/0.03 NA R.PRC 0.03/0.06 NA 
R.PHC 0.03/0.09 NA R.RAC 0.08/0.02 NA 






R.PB 0.04/0.08 NA R.SF 0.09/0.08 NA 
R.PTR 0.04/0.03 NA R.ST 0.07/0.04 NA 
R.PCC 0.09/0.01 NA R.SM 0.03/0.05 NA 
R.POC 0.05/0.05 NA R.TP 0.04/0.06 NA 
R.PCG 0.09/0 NA R.TT 0/0.01 NA 
  
 
Figure e-3. Color-coded representation of P values corresponding to the 
associations of C9orf72 mutation with the subcortical ROI measures before 
correction for multiple comparisons. 





Table e-3. Effect sizes for FWF metrics and gray matter volume in 
subcortical regions. 
The effect sizes for both FWF and gray matter volume in subcortical regions are shown below.  
For regions for which a significant difference between C9+ and C9- was detected for any of the 
metrics, we compared the effect size of FWF to that of volumetry using a permutation test 
procedures with 10000 iterations. The table presents the P values corresponding to these 
permutation tests (with a significance level of P < 0.05). For FWF effect size analysis, 6 ROIs 
were excluded because, after the 2-voxel erosion procedure, they were too small to produce 
reliable regional estimates. 
 
Abbreviations: CB, cerebellum cortex; VD, ventral diencephalon; PUT, putamen; PAL, 
pallidum; CAU, caudate; ACC, accumbens area; THA, thalamus; HIP, hippocampus; FWF, 
free water fraction; NA, not applicable. 
 
 
ROI Effect size 
(FWF/Volumetry) 
P value ROI Effect size 
(FWF/Volumetry) 
P value 
L. CB  NA/0 NA R.CAU 0.01/0 NA 






L.VD NA/0 NA R.ACC NA/0 NA 
R.VD NA/0 NA L.AMY 0/0.03 NA 
L.PUT 0.05/0.03 NA R.AMY 0/0.04 NA 
R.PUT 0.03/0.05 NA L.THA 0.06/0.05 NA 
L.PAL 0/0.02 NA R.THA 0.03/0.16 0.062 
R.PAL 0.09/0.02 NA L.HIP 0/0.10 NA 
L.CAU 0.02/0.00 NA R.HIP 0/0.11 NA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
